Compare SHMD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | FHTX |
|---|---|---|
| Founded | 1864 | 2015 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.0M | 332.2M |
| IPO Year | N/A | 2020 |
| Metric | SHMD | FHTX |
|---|---|---|
| Price | $6.32 | $4.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 780.1K | 126.7K |
| Earning Date | 01-01-0001 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $14.62 |
| Revenue Next Year | N/A | $15.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $2.00 | $2.94 |
| 52 Week High | $10.65 | $6.95 |
| Indicator | SHMD | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 35.07 |
| Support Level | $2.38 | $4.44 |
| Resistance Level | $6.70 | $5.85 |
| Average True Range (ATR) | 0.98 | 0.37 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 14.78 | 15.75 |
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.